Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117194332 | 11719433 | 2 | F | 2010 | 20160812 | 20151110 | 20160824 | EXP | CA-PFIZER INC-2014206975 | PFIZER | 48.00 | YR | F | Y | 0.00000 | 20160824 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117194332 | 11719433 | 1 | PS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 20 MG, ALTERNATE DAY (EVERY SECOND DAY) | 21106 | 20 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | QOD | ||||||
| 117194332 | 11719433 | 2 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 20 MG, EVERY TWO DAYS | 21106 | 20 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | |||||||
| 117194332 | 11719433 | 3 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 40 MG, ALTERNATE DAY (EVERY SECOND DAY) | 21106 | 40 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | QOD | ||||||
| 117194332 | 11719433 | 4 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 15 MG, ALTERNATE DAY (EVERY 2ND DAY) | 21106 | 15 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | QOD | ||||||
| 117194332 | 11719433 | 5 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 25 MG, EVERY OTHER DAY | 21106 | 25 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | QOD | ||||||
| 117194332 | 11719433 | 6 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 20 MG EVERY 2ND DAY | 21106 | 20 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | QOD | ||||||
| 117194332 | 11719433 | 7 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 117194332 | 11719433 | 8 | C | TELMISARTAN. | TELMISARTAN | 1 | UNK | 0 | |||||||||||
| 117194332 | 11719433 | 9 | C | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | 20 MG, EVERY 3 WEEKS | 0 | 20 | MG | Q3W |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 117194332 | 11719433 | 1 | Acromegaly |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 117194332 | 11719433 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 117194332 | 11719433 | Abdominal distension | |
| 117194332 | 11719433 | Injection site haemorrhage | |
| 117194332 | 11719433 | Injection site swelling | |
| 117194332 | 11719433 | Pituitary tumour benign |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 117194332 | 11719433 | 1 | 2010 | 0 | ||
| 117194332 | 11719433 | 2 | 2011 | 0 |